Chimeric Antigen Receptor Design Today and Tomorrow. Issue 2 (March 2021)

• Record Type: Journal Article
• Authors: Boucher, Justin C.; Davila, Marco L.
• Is Part Of: Cancer journal. Volume 27:Issue 2(2021)
• Page Start: 92
• Page End: 97
• Publication Date: 2021-03
• Subjects: Boolean logic gating -- costimulation -- multifunctional CAR; Cancer -- Periodicals; 616.994005
• DOI: 10.1097/PPO.0000000000000514
• Languages: English
• ISSNs: 1528-9117

Abstract

Abstract: The US Food and Drug Administration has approved 3 chimeric antigen receptor (CAR) T-cell therapies. For continued breakthroughs, novel CAR designs are needed. This includes different antigen-binding domains such as antigen-ligand binding partners and variable lymphocyte receptors. Another recent advancement in CAR design is Boolean logic gates that can minimize on-target, off-tumor toxicities. Recent studies on the optimization of costimulatory signaling have also shown how CAR design can impact function. By using specific signaling pathways and transcription factors, CARs can impact T-cell gene expression to enhance function. By using these techniques, the promise of CAR T-cell therapies for solid tumors can be fulfilled.